Novel Diabetes Drugs and the Cardiovascular Specialist-Reference-Cited by-同舟云学术

Novel Diabetes Drugs and the Cardiovascular Specialist

Published:2017-05 Issue:21 Volume:69 Page:2646-2656
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Sattar Naveed,Petrie Mark C.,Zinman Bernard,Januzzi James L.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference53 articles.

1. Cardiovascular outcome studies with novel antidiabetes agents: scientific and operational considerations;Hirshberg;Diabetes Care,2013

2. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015

3. Liraglutide and cardiovascular outcomes in type 2 diabetes;Marso;N Engl J Med,2016

4. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes;Marso;N Engl J Med,2016

5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S);Lancet,1994

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stimuli-Responsive Boron-Based Materials in Drug Delivery;International Journal of Molecular Sciences;2023-02-01

2. Novel Therapeutics for Type 2 Diabetes, Obesity, and Heart Failure;Journal of Cardiopulmonary Rehabilitation and Prevention;2023-01

3. New Antidiabetic Agents: Relevance to Cardiovascular Outcomes;Blood Pressure Disorders in Diabetes Mellitus;2023

4. Vascular disease prevention and management after cancer therapy;Cardio-Oncology Practice Manual : a Companion to Braunwald 's Heart Disease;2023

5. Prevalence of cardiovascular events among patients with type 2 diabetes in the west region of Saudi Arabia;Saudi Pharmaceutical Journal;2022-12